China Universal CNI BIOMEDICINE ETF

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Fosun Pharma: Expected to submit NDA by year-end

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

Hangzhou Therapeutic Biotechnology Proposes Up to 100 Million Yuan Stock Repurchase Plan

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

CSO 实际控制 persons under investigation for disclosure violations related to shareholding changes

Belayidiantianheng Receives Approval for Clinical Trials of Iza-bren Combination Therapy

300医药

中证医疗

159839

000037

560260

159837

512170

<p>As of April 6, 112 biopharmaceutical companies in the A-share market have disclosed their annual reports, with 60 companies showing a year-on-year increase in net profit attributable to shareholders, among which 40 companies experienced growth in both revenue and net profit. Some companies have seen growth due to increased commercialization of innovative drugs and revenue from external licensing, while others are facing pressure due to strategic adjustments. Currently, the development characteristics of the pharmaceutical industry are evident, with deepening reforms on the payment side, innovative leaps on the supply side, restructuring of health service models, and diversification of consumer demand. Among the 40 companies with dual growth, 16 have seen a net profit increase of over 50%</p>

腾讯新闻 - 财经

SSE Health Care

GF Fund CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

Biomedicine Sector Performance Scan: 40 Companies with Double Growth, 29 Companies with Double Decline, Driven by "Innovation + Going Global"

159102

516930

520880

<p>In 2026, the business expansion transactions of China's innovative drugs continued to heat up, with 44 external licensing transactions occurring within the year, totaling over USD 53 billion, with an upfront payment of approximately USD 3.123 billion</p>

Wallstreetcn

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Universal Hang Seng Biotechnology Technology ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB CSI Hugangshen Innovative Drugs Industry ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Fullgoal Hang Seng Biotech ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Huatai-PB Hang Seng Biotech ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI Innovative Drugs Industry ETF

Guotai Hang Seng Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year

China Universal CNI BIOMEDICINE ETF(159839.SZ)

Biomedicine Sector Performance Scan: 40 Companies with Double Growth, 29 Companies with Double Decline, Driven by "Innovation + Going Global"

Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year